(Q84582212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Natalizumab for multiple sclerosis: a complicated treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

B Mark Keegan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

677-678

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970150-8

7 January 2021

10.1016/S1474-4422(11)70150-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21777819%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference